Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study

Journal of the American College of Cardiology

Volumn 31, Issue 3, 1998, Pages 519-525

  Cantin, Bernard ^a   Gagnon, France ^b   Moorjani, Sital ^a   Després, Jean Pierre ^a   Lamarche, Benoit ^a   Lupien, Paul Joseph ^a   Dagenais, Gilles R ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; FEMALE; FOLLOW UP; HEMOSTASIS; HUMAN; HYPOLIPEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; BLOOD PRESSURE; CORONARY DISEASE; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUEBEC; RISK FACTORS; SMOKING;

EID: 18144438859     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00528-7     Document Type: Article

References (48)

1. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease a prospective case-control study in a general population sample of middle-aged men . BMJ. 301:1990;1248-1251.
2. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein(a) and coronary heart disease risk a nested case-control study of the Helsinki Heart Study participants . Atherosclerosis. 89:1991;59-67.
3. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 69:1992;1251-1254.
4. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population evidence for the role of the apo(a) gene in coronary heart disease . J Clin Invest. 89:1992;1040-1046.
5. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men the Lipid Research Clinics Coronary Primary Prevention trial . JAMA. 271:1994;999-1003.
6. Rader DJ, Hoeg JM, Brewer HBJ. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 120:1994;1012-1025.
7. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after balloon coronary angioplasty. Circulation. 91:1995;1403-1409.
8. Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakido M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty role of lipoprotein(a) . Am Heart J. 130:1995;1168-1173.
9. Tamura A, Watanabe T, Mikuriya Y, Nasu M. Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction. Br Heart J. 74:1995;365-369.
10. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation. 91:1995;948-950.
11. Költringer P, Jürgens G. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis. 58:1985;187-198.
12. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 59:1986;199-204.
13. Zenker G, Költringer P, Boné G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 17:1986;942-945.
14. Mölgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb. 12:1992;895-901.
15. Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med. 154:1994;801-806.
16. Cantin B, Moorjani S, Dagenais GR, Lupien PJ. Lp(a) distribution in a French Canadian population and its relation to intermittent claudication (the Quebec Cardiovascular Study). Am J Cardiol. 75:1995;1244-1248.
17. Ridker PM, Hennekens CH, Stamfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 270:1993;2195-2199.
18. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease implications for screening . Lancet. 343:1994;75-79.
19. Cremer P, Nagel D, Labrot B, et al. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS) . Eur J Clin Invest. 24:1994;444-453.
20. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger a prospective study . JAMA. 276:1996;544-548.
21. Coleman MP, Key TJA, Wang DY, et al. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis. 92:1992;177-185.
22. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis. 106:1994;9-19.
23. Salomaa V, Rasi V, Pekkanen J, et al. Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. Eur Heart J. 15:1994;1293-1299.
24. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype according to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 322:1990;1494-1499.
25. Dagenais GR, Maurice S, Robitaille NM, Gingras S, Lupien PJ. Intermittent claudication in Quebec men from 1974-1986 the Quebec Cardiovascular Study . Clin Invest Med. 14:1991;93-100.
26. Havel RJ, Eder HA, Bragdon HA. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1353.
27. Burstein M, Samaille J. Sur un dosage rapide du cholestérol lié aux α et aux β-lipoprotéines du sérum. Clin Chim Acta. 5:1960;609.
28. Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high density lipoproteins concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 36:1987;244-250.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
30. Laurell CB. Electroimmuno assay. Scand J Clin Lab Invest. 29:(Suppl 124):1972;21-37.
31. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc B. 34:1972;187-220.
32. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes a 26-year follow-up of the Framingham population . Am Heart J. 111:1986;383-390.
33. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 269:1993;3015-3023.
34. Multiple risk factor intervention trial risk factor changes and mortality results . JAMA. 248:1982;1465-1477.
35. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
36. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense, low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation. 95:1997;69-75.
37. Berg K. Confounding results of Lp(a) lipoprotein measurements with some test kits. Clin Genet. 46:1994;57-62.
38. Labeur C, Rosseneu M. Methods for the measurement of lipoprotein(a) in the clinical laboratory. Curr Opin Lipidol. 3:1992;372-376.
39. Craig WY, Poulin SE, Forster NR, Neveux LM, Wald NJ, Ledue TB. Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits. Clin Chem. 38:1992;550-553.
40. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time why epidemiological studies might fail . Arterioscler Thromb Vasc Biol. 16:1996;1568-1572.
41. Chapman MJ, Huby T, Nigon F, Thillet J. Lipoprotein(a) implication in atherothrombosis . Atherosclerosis. 110:(Suppl):1994;S69-S75.
42. Sattler W, Kostner GM, Waeg G, Estebauer H. Oxidation of lipoprotein Lp(a) a comparison with low-density lipoproteins . Biochim Biophys Acta. 1081:1991;65-74.
43. Naruszewicz N, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of β-carotene. Metabolism. 41:1992;1215-1224.
44. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of Lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 267:1992;4143-4151.
45. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
46. Loscalzo J, Weinfield M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 10:1990;240-245.
47. Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry. 30:1991;6671-6677.
48. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 274:1995;1771-1774.